• Explore /
  • Poster
  • / A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.

A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.

Abstract Poster

Authors

null

Takashi Ishikawa

Department of Breast and Thyroid Surgery, Yokohoma City University Medical Center, Yokohama, Japan

Takashi Ishikawa , Daisuke Shimizu , Mikiko Tanabe , Mari S.Oba , Takeshi Sasaki , Satoshi Morita , Kumiko Kida , Shuichi Nawata , Masatoshi Mogaki , Takako Doi , Koichiro Tsugawa , Haruki Ogata , Yoshimasa Kosaka , Norihiko Sengoku , Yasuhiro Suzuki , Akihiko Suto , Takashi Chishima , Yasushi Ichikawa , Itaru Endo , Yutaka Tokuda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Triple-Negative Breast Cancer

Clinical Trial Registration Number

UMIN000002215

Citation

J Clin Oncol 31, 2013 (suppl; abstr 1047)

DOI

10.1200/jco.2013.31.15_suppl.1047

Abstract #

1047

Poster Bd #

19F

Abstract Disclosures

Similar Posters

First Author: M. Luque

First Author: Naoko Matsuda

First Author: Kenji Higaki

First Author: Tarek Mohamed Ahmed Abdel-Fatah